

YaleNewHavenHealth

Smilow Cancer Hospital

Yale CANCER CENTER

A Comprehensive Cancer Center Designated
by the National Cancer Institute

Grand Rounds

Join us
in person
for lunch!

TUESDAY, April 4, 12:00pm

Zoom Access

Peritoneal Surface Malignancies: Novel therapeutics and insights



Kiran Turaga, MD, MPH

Chief, Surgical Oncology; Assistant Medical Director, Yale Cancer Center Clinical Trials Office

Needs: There are many new advances in the use of novel therapeutics for peritoneal surface malignancies. Discuss what these are and how they can be utilized. Historically, the outlook for patients with peritoneal surface malignancies has been dismal due to limited therapeutic options.

Objectives: Discuss new therapeutic options available. Significant advances including the early application of intraperitoneal chemotherapy and cytoreductive techniques, in addition to advances in systemic chemotherapy, have improved the overall prognosis.



Continuing Medical Education
Yale CME



There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: YCC members, Smilow faculty, YSM, Nursing, Public Health Students. Faculty Disclosures: Winer- nothing to disclose. Turaga- Consultant | Merck. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. Mitigation of Financial Relationships Statement: Yale CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.